239
Participants
Start Date
November 14, 2014
Primary Completion Date
December 11, 2015
Study Completion Date
December 11, 2015
NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler
Micronized 400 mcg budesonide+ 12 mcg formoterol fumarate along with micronized and crystalline lactose monohydrate (excipient), per capsule dispensed by single capsule inhaler, twice daily (administered once in the morning and once in the evening approximately 12 hours later).
SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler
Unit dose containing 320 mcg budesonide and 9 mcg formoterol fumarate (as dihidrate) along with lactose monohydrate as excipient. Administered as inhalation by TURBUHALER inhaler, twice daily (once in the morning and once in the evening approximately 12 hours later)
NEUMOTEX 400 (Budesonide 400 mcg)
Budesonide 400mcg will be administered to all the subjects twice daily, during the Run-in and Washout Periods
Salbutamol 100 mcg pMDI
Salbutamol 100mcg will be administered as pMDI on demand, as rescue medication, throughout the entire study period until Visit 5
GSK Investigational Site, Monte Grande
GSK Investigational Site, Berazategui
GSK Investigational Site, La Plata
GSK Investigational Site, Rosario
GSK Investigational Site, Rosario
GSK Investigational Site, Mar del Plata
GSK Investigational Site, Ciudad Autónoma de Buenos Aires
GSK Investigational Site, Mar del Plata
GSK Investigational Site, Vicente López
GSK Investigational Site, Berazategui, Buenos Aires
GSK Investigational Site, Buenos Aires
Lead Sponsor
GlaxoSmithKline
INDUSTRY